药明康德本月股价涨幅已达41.90%。在昨日发布营收、净利均同比双位数增长的半年报后，今日药明 康德A股上涨7.72%，报收98.69元/股；H股上涨11.25%，报收111.70港元/股。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经7月29日讯（记者 武超 卢阿峰）近阶段，医药板块持续升温，频频释放利好的药明康德 （603259.SH）股价也持续攀升，现已恢复至3年前的位置。而公司今晚一则"调高回购股份价格上限"的 公告，则进一步显露出对未来的信心。 据公告，药明康德拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限由不超过 90.72元/股（含）调整为不超过114.15元/股，即不高于董事会通过本次决议前30个交易日公司股票交易 均价的150%。 此前，药明康德审议通过《关于2025年以集中竞价交易方式回购公司A股股份的议案》，同意公司以总 额为10亿元的自有资金和自筹资金、以集中竞价交易方式回购公司 ...

尤为值得关注的是，今年以来，恒生港股通创新药精选指数年内累计上涨107.56%，领涨一众创新药指数。目前场内唯一跟踪该指数的港股通创新 药ETF（520880）今日场内价格豪涨5.06%，收盘涨幅霸居全市场所有ETF第一！ 基金经理丰晨成认为，港股+创新药是今年的主题主线，而不是短期概念炒作。行业周期向上趋势明显，这是今年创新药引领市场的根本原因，而 基本面财务数据出现明显回暖趋势，是源于创新药企扭亏为盈的企业越来越多，因为成本摊销都在研发早期，后期新药可销售后，其利润弹性更 大。 今日（7月29日）A股三大指数继续上涨，沪指站上3600点，深证成指与创业板指再创年内新高！沪深两市成交额达1.8万亿元，较昨日放量609亿 元。 盘面上，药明康德业绩亮眼，CXO全线沸腾，A股最大医疗ETF（512170）场内价格劲涨2.45%，成功斩获日线10连阳，刷新历史最长连阳纪录！ 或由于上海将发放6亿元算力券，光模块三巨头放量突破！中际旭创跳涨超9%股价创新高，新易盛涨超8%股价再创新高，成交额居A股首位，天 孚通信暴涨超13%放量突破！光模块含量突出的人工智能指数——创业板人工智能ETF（159363）场内价格收涨3 ...

Group 1 - The core viewpoint of the articles highlights the performance of various indices related to the Hong Kong stock market, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 4.0% [1] - The Hang Seng Hong Kong Stock Connect New Economy Index increased by 0.5%, while the China Securities Hong Kong Stock Connect Internet Index and the Hang Seng Technology Index decreased by 0.2% and 0.4% respectively [1] - According to Guangfa Securities, the rise of China's innovative drugs from a global perspective is catalyzed by the overseas expansion of BD, leading to a revaluation of new drug value [1] Group 2 - The Hang Seng New Economy ETF tracks the Hang Seng Hong Kong Stock Connect New Economy Index, which consists of the 50 largest stocks in the "new economy" sector within the Hong Kong Stock Connect range [2] - The rolling price-to-earnings ratio of the Hang Seng New Economy Index is 23.6 times, with a valuation percentile of 47.4% since its inception in 2018 [2] - The Hang Seng Technology ETF tracks the Hang Seng Technology Index, which includes the 30 largest stocks related to technology, with a rolling price-to-earnings ratio of 21.6 times and a valuation percentile of 20.5% since its launch in 2020 [2] Group 3 - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of 50 highly liquid and large-cap stocks in the healthcare sector, with a weight of over 90% in the industry [3] - This index has a rolling price-to-earnings ratio of 32.5 times and a valuation percentile of 50.0% since its inception in 2017 [3] - The China Securities Hong Kong Stock Connect Consumer Theme Index is composed of 50 large-cap consumer stocks, with nearly 60% in discretionary consumption, and has a rolling price-to-earnings ratio of 21.0 times and a valuation percentile of 17.1% since its launch in 2020 [3]

"未来已来"指数今日上涨，截至收盘，恒生港股通创新药指数上涨4.4%，中证人工智能主题指数上涨2.6%，中证云计算与大数据主题指数上涨2.3%，中证 新能源指数上涨0.9%，国证机器人产业指数上涨0.4%。 | 该指数聚焦云计算产业, | | | | | --- | --- | --- | --- | | 覆盖各类计算设备和计算 | マ日 | 该指数 | 该指数自20 | | 服务相关领域,由业务涉 | 该指数涨跌 | 滚动市销率 | 发布以来估1 | | 及提供云计算服务、大数 | | | | | 据服务以及相关硬件设备 的股票组成。 | 2.3% | 4.0倍 | 93.89 | | 恒生创新药ETF ONLY | | | 159: | | 跟踪恒生港股通创新药指数 | | | | | | | | ·· | | 该指数聚焦创新药产业, | �日 | 该指数 | 该指数 | | 由业务涉及创新药研究、 | 该指数涨跌 | 滚动市盈率 | | | 开发及生产的港股通股票 | | | | | 组成,汇聚前沿创新药企 | 4.4% | 34.3倍 | 2023年7月 | | 小石 | | | 发布 | | 新能源 ...

Core Viewpoint - The company has recently launched two new drugs, Maraslosavir Tablets and Pediatric Constipation Granules, which are categorized as innovative drugs and are expected to impact the company's performance positively [2]. Group 1: Drug Development and Approval - Maraslosavir Tablets is a Class 1 new chemical drug developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd., and has been approved for market launch [2]. - Pediatric Constipation Granules is a Class 1 innovative traditional Chinese medicine that has had its market approval application accepted, and the company is actively working on subsequent processes [2]. Group 2: Market Impact and Risks - The sales of these products may be influenced by changes in domestic pharmaceutical industry policies, tender procurement, and market environment, indicating potential uncertainties in their market performance [2].

7月29日，受"CXO一哥"药明康德业绩回暖的提振，整个CXO板块沸腾。其中，港股泰格医药盘中大涨 超10%，拉长时间线来看，自4月9日的股价低点以来，公司股价累计大涨136%。泰格医药A股盘中也涨 超13%，股价最高达71.71元/股，创2025年以来新高。 值得一提的是，身为CRO龙头的泰格医药酷爱投资，从参投基金做LP、一级市场直投到二级市场"炒 股"，公司均有涉猎。 而随着创新药牛市的到来，泰格医药在一二级市场投资的创新药公司有望迎来估值提升，公司也能"分 一杯羹"。7月17日，泰格医药刚公告公司持有的礼新医药股份被中国生物制药收购。今年4月刚登陆港 股的映恩生物背后，也有泰格医药的身影。 回溯以往，泰格医药的投资收益一度占公司归母净利润的一半以上，成功"反哺"公司的CRO业务。但需 要注意的是，这种业务模式受行业景气度影响较大，"常在河边走，哪有不湿鞋"，2024年，公司归母净 利润暴跌近80%，其中就有投资收益下滑的影响。 泰格医药4个月涨136% 7月29日，A股CRO板块大涨4%，其中泰格医药盘中涨超13%，股价最高达71.71元/股，创2025年以来新 高。截至收盘，涨幅回落至8.8%，报6 ...

| 序号 | 证券代码 | 证券简称 | 区间涨跌幅 | | | --- | --- | --- | --- | --- | | | | | [区间首日] 本年初 【X间尾日 2025-7-29 1017791 | | | 1 | HSSCPB.HI | 恒生港股通创新约精选 | | 107.5601 | | 2 | | 931787CNY00.CSI 港股创新药(CNY) | | 96.6493 | | 3 | HSSSHID HI | 恒生沪深港创新药50 | | 58.2013 | | 4 | 931409.CSI | SHS创新药 | | 56.5152 | | 5 | 931440.CSI | 创新药30 | | 44.4602 | | 6 | 931152.CSI | CS创新药 | | 34.3063 | 港股创新药又爆了！高纯度+高弹性标的港股通创新药ETF（520880）涨势如虹，场内价格大幅收涨 5.06%，登上全市场ETF涨幅第一，续刷历史新高！ | 序号 代码 | 类型 名称 | 现价 | 涨跌 涨跌幅 ▼ | | --- | --- | --- | --- | | 520880 | ...

Market Overview - A-shares continued to rise, with the Shanghai Composite Index surpassing 3600 points and both the Shenzhen Component Index and the ChiNext Index reaching new highs for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.8 trillion yuan, an increase of 609 billion yuan from the previous day [1] Sector Performance - WuXi AppTec reported strong earnings, leading to a surge in the CXO sector, with the largest medical ETF (512170) rising by 2.45%, achieving a record 10 consecutive days of gains [1] - The Hong Kong Stock Connect Innovation Drug ETF (520880) saw a significant increase of 5.06%, marking the highest gain among all ETFs in the market [1][5] Innovation Drug Sector - The Hang Seng Hong Kong Stock Connect Innovation Drug Index has risen by 107.56% year-to-date, outperforming other innovation drug indices [1] - Fund manager Feng Chen emphasized that the theme of Hong Kong stocks and innovative drugs is a long-term trend rather than a short-term speculative play, supported by a clear upward industry cycle [1][5] Policy and Economic Factors - Shanghai plans to issue 600 million yuan in computing power vouchers to reduce costs and support AI applications [2] - The Ministry of Industry and Information Technology held a meeting to discuss enhancing consumer goods supply and demand adaptability, promoting new industrial development, and improving standards in industries like photovoltaics [3] Investment Insights - Analysts suggest that the current bull market is being reinforced by increased capital inflows and improving fundamentals, with a focus on sectors like aviation equipment, wind power, and digital economy [3] - The CXO sector is expected to benefit from increased domestic demand for new drug research and development, as well as a favorable external environment for contract development and manufacturing organizations (CDMO) [12] AI and Computing Power Sector - The AI-focused ChiNext Artificial Intelligence ETF (159363) rose by 3.82%, reaching a new high, driven by strong performance in the optical module sector [1][14] - The optical module market is projected to grow significantly, with sales expected to reach 19.9 million units in 2025 and 33.5 million units in 2026, reflecting a robust growth trajectory [19] Company Highlights - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of the year, a year-on-year increase of 20.64%, with a net profit of 8.287 billion yuan, up 95.5% [10][12] - The company announced a mid-year dividend of 1 billion yuan and raised its full-year revenue growth forecast to 13%-17% [10][12]

7月29日，A股市场主要指数全线飘红，科技成长风格表现亮眼，主线切换逻辑愈加清晰。 港股市场行业分化显著，医疗保健业涨3.77%，恒生港股通创新药精选指数大涨4.43%；工业、能源板 块分别涨1.34%、0.89%。资讯科技业跌0.72%，金融业跌0.59%，恒生港股通中国内地银行指数跌 1.51%。概念板块中反恐指数、CRO指数领涨，大气治理、券商板块跌幅居前。 当前市场呈现三大特征：一是结构性行情突出，科技成长与传统板块分化加剧；二是政策驱动效应显 著，工信部关于人工智能终端、人形机器人等产业政策的部署，以及国家育儿补贴政策落地，持续引导 资金流向硬科技及消费领域；三是资金博弈加剧，热点轮动从"赛道抱团"转向"细分领域轮动"，医药、 算力、半导体等板块交替成为领涨主线，同时港股与A股联动性增强，特别是在医药、银行等板块形成 跨市场共振。。 策略上，短期建议紧扣资金动向，关注业绩确定性强的创新药、半导体设备等板块，政策催化下的人工 智能终端产业链，以及暑期档超预期的影视传媒行业。 中期可布局产业变革带来的长期红利，重点把握三大方向：一是泛科技领域，包括半导体国产替代、算 力基础设施、人形机器人核心零部件；二 ...

| 中芯国际 | 6.421Z | 5.18 亿 | 11.60亿 | | --- | --- | --- | --- | | HK 00981 | | | +1.24 亿 | | 快手-W | 4.62亿 | 4.71亿 | 9.33亿 | | HK 01024 | | | -850.31万 | | 石药集团 | 5.88亿 | 3.24亿 | 9.11亿 | | HK 01093 | | | +2.64 乙 | | 信达生物 | 6.77 亿 | 1.62亿 | 8.39亿 | | HK 01801 | | | +5.141Z | | 泡泡玛特 | 3.63亿 | 4.43亿 | 8.06亿 | | HK 09992 | | | -7973.47万 | 港股通(深)活跃成交股 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 小米集团-W HK 01810 | 31.76亿 | 21.87 亿 | 53.64亿 | | | | | +9.89 亿 | | 国泰君安 ... | 21.58亿 | 19.90亿 | 41 ...